Table 1.
Patient demographics and clinical characteristics
| Variables | N | % |
|---|---|---|
| No. of patients | ||
| Eligible | 22 | |
| Assessable for toxicity | 21 | 100 |
| Assessable for response | 21 | 100 |
| Assessable for pharmacokinetics | 21 | 100 |
| Age | ||
| Median years (range) | 64 | (37–77) |
| Sex | ||
| Female | 17 | 81 |
| Disease history | ||
| Ovarian | 13 | 62 |
| Bladder | 1 | 5 |
| Brain | 1 | 5 |
| Endometrium | 1 | 5 |
| Gastroesophageal junction | 1 | 5 |
| Pancreas | 1 | 5 |
| Peritoneum | 1 | 5 |
| Small bowel | 1 | 5 |
| Adenocarcinoma (location not specified) | 1 | 5 |
| Cancer stage at initial diagnosis | ||
| I | 1 | 5 |
| II | 1 | 5 |
| III | 1 | 5 |
| IIIA | 1 | 5 |
| IIIC | 9 | 43 |
| IV | 8 | 38 |
| No. of patients with previous surgical procedures | 21 | 100 |
| Tumor debulking | 7 | 33 |
| No. of patients with previous chemotherapies | 21 | 100 |
| Carboplatin and IV paclitaxel | 16 | 76 |
| IP chemotherapy | 2 | 10 |